JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Richardson, D. W.
Right arrow Articles by Patterson, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richardson, D. W.
Right arrow Articles by Patterson, J. L., Jr.
Journal of Pharmacology And Experimental Therapeutics, Vol. 119, Issue 2, 219-224, 1957
Copyright © 1957 by American Society for Pharmacology and Experimental Therapeutics

EFFECTS OF MEPHENTERMINE ON CEREBRAL METABOLISM AND CIRCULATION

David W. Richardson 1, Robert W. Ferguson 1, and John L. Patterson Jr. 1

1 Department of Medicine, Medical College of Virginia, Richmond, Virginia

Mephentermine, a synthetic sympathomimetic amine, significantly increased cerebral oxygen utilization by 24 per cent when effective pressor doses were administered intravenously to normal subjects. Cerebral blood flow and vascular resistance were not markedly altered.

Comparison of the structure of the four sympathomimetic amines whose effects on the cerebral circulation and metabolism have been studied suggests that modification of their chemical structure might result in a more nearly ideal pressor substance.

Submitted on August 10, 1956






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1957 by the American Society for Pharmacology and Experimental Therapeutics.